Price T Rowe Associates Inc. MD Has $15.80 Billion Holdings in Eli Lilly and Company $LLY

Key Points

• Price T Rowe Associates Inc. MD reduced its holdings in Eli Lilly and Company by 8.3%, owning approximately 19.1 million shares valued at $15.8 billion after the sale.
• Analysts have mixed opinions on Eli Lilly, with Cantor Fitzgerald lowering their price target to $825, while the overall consensus rating is a "Moderate Buy" with an average price target of $950.17.
• Eli Lilly has announced a quarterly dividend of $1.50 per share, representing an annualized dividend of $6.00 and a yield of 0.9%, with an upcoming payout scheduled for September 10th.

Price T Rowe Associates Inc. MD lowered its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 8.3% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 19,133,284 shares of the company's stock after selling 1,730,684 shares during the period. Eli Lilly and Company makes up 1.9% of Price T Rowe Associates Inc. MD's portfolio, making the stock its 6th largest holding. Price T Rowe Associates Inc. MD owned 2.02% of Eli Lilly and Company worth $15,802,371,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in the company. Knightsbridge Asset Management LLC increased its position in Eli Lilly and Company by 1.9% during the fourth quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock worth $628,000 after acquiring an additional 15 shares during the period. Corient IA LLC bought a new position in shares of Eli Lilly and Company during the first quarter worth approximately $570,000. LS Investment Advisors LLC raised its position in shares of Eli Lilly and Company by 1.7% in the first quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock valued at $1,933,000 after buying an additional 40 shares in the last quarter. Prism Advisors Inc. acquired a new stake in shares of Eli Lilly and Company in the first quarter valued at approximately $207,000. Finally, CSM Advisors LLC boosted its stake in shares of Eli Lilly and Company by 30.6% in the fourth quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock valued at $807,000 after buying an additional 245 shares during the period. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Up 0.1%

NYSE:LLY traded up $0.9090 during trading hours on Friday, hitting $710.7290. 3,217,264 shares of the company were exchanged, compared to its average volume of 6,973,298. The stock has a market capitalization of $672.68 billion, a price-to-earnings ratio of 46.45, a price-to-earnings-growth ratio of 0.99 and a beta of 0.44. Eli Lilly and Company has a one year low of $623.78 and a one year high of $972.48. The company has a fifty day simple moving average of $754.70 and a 200 day simple moving average of $790.90. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter in the prior year, the firm posted $3.92 earnings per share. The business's quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is currently 39.22%.

Insiders Place Their Bets

In related news, Director J Erik Fyrwald acquired 1,565 shares of the stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the purchase, the director directly owned 74,578 shares of the company's stock, valued at $47,903,686.74. The trade was a 2.14% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gabrielle Sulzberger acquired 117 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the transaction, the director directly owned 2,703 shares in the company, valued at approximately $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 4,514 shares of company stock valued at $2,894,841 over the last quarter. Company insiders own 0.13% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. HSBC cut Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their price target for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. DZ Bank upgraded Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. UBS Group lowered their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a report on Friday, August 8th. Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Finally, Leerink Partners reiterated a "market perform" rating and issued a $715.00 target price on shares of Eli Lilly and Company in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and an average price target of $950.17.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.